Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry
- 1 December 1996
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 23 (12) , 1588-1593
- https://doi.org/10.1007/bf01249621
Abstract
The noninvasive staging of axillary lymph nodes for metastases is investigated in patients with breast cancer prior to surgery by positron emission tomography (PET) with fluorine- l8-fluoro-2-deoxy-d-glucose (18F-FDG). In 124 patients with newly diagnosed breast cancer, whole-body PET was performed to determine the average differential uptake ratio (DUR) of18F-FDG in the axillary lymph nodes. Results were correlated with the number of the dissected lymph nodes, size of the primary tumor, tumor type, tumor grade, estrogen and progesterone receptors, DNA ploidy, and the proportion of cells in the synthetic phase of the cell cycle (S-phase). In this prospective study of 124 patients with breast carcinoma, PET correctly categorized all 44 tumor-positive axillary lymph nodes, a sensitivity of 100%. Sixty tumor-negative axillary lymph nodes were negative by PET and 20 tumor-negative axillary lymph nodes were positive by PET. No false-negative PET findings were encountered. A weak correlation was found between DUR and tumor size as well as between DUR and the S-phase of the tumor. In patients with breast carcinoma,18F-FDG PET can be of value in evaluating axillary lymph nodes for metastatic involvement prior to surgery. It is of particular importance that no false-negative PET findings were encountered, and axillary lymph node dissection might not be necessary in patients without axillary uptake by PET. The DUR of the positive axillary lymph nodes seems to bear a relationship with some of the purported prognostic parameters of the primary tumor.Keywords
This publication has 24 references indexed in Scilit:
- Positron Emission Tomography of Glucose Metabolism in Breast CancerAnnals of the New York Academy of Sciences, 1993
- Cancer Detection with Whole-Body PET Using 2-[18F]Fluoro-2-Deoxy-D-GlucoseJournal of Computer Assisted Tomography, 1993
- Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancerCancer, 1993
- Cancer statistics, 1993CA: A Cancer Journal for Clinicians, 1993
- The Application of Positron Emission Tomographie Imaging With Fluorodeoxyglucose to the Evaluation of Breast DiseaseAnnals of Surgery, 1992
- Prognostic Factors and Treatment Decisions in Axillary-Node-Negative Breast CancerNew England Journal of Medicine, 1992
- Indicators of Prognosis in Node-Negative Breast CancerNew England Journal of Medicine, 1990
- Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial.BMJ, 1988
- Discontinuous or “Skip” Metastases in Breast Carcinomae: Analysis of 1228 Axillary DissectionsAnnals of Surgery, 1983
- Glucose utilization of cerebral gliomas measured by [ 18 F] fluorodeoxyglucose and positron emission tomographyNeurology, 1982